Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 08 Jun 2017
At a glance
- Drugs Amantadine (Primary)
- Indications Drug-induced dyskinesia
- Focus Adverse reactions
- Acronyms EASE LID 2
- Sponsors Adamas Pharmaceuticals
- 08 Jun 2017 Interim (n=223) results presented at the 21st International Congress of Parkinson's Disease and Movement Disorders.
- 08 Jun 2017 According to an Adamas Pharmaceuticals media release, results from this study were presented at the 21st International Congress of Parkinsons Disease and Movement Disorders.
- 08 Jun 2017 Results published in an Adamas Pharmaceuticals, Inc. media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History